vs
Side-by-side financial comparison of Hologic (HOLX) and Jackson Financial Inc. (JXN). Click either name above to swap in a different company.
Jackson Financial Inc. is the larger business by last-quarter revenue ($2.0B vs $1.0B, roughly 1.9× Hologic). Hologic runs the higher net margin — 17.1% vs -10.3%, a 27.4% gap on every dollar of revenue. On growth, Jackson Financial Inc. posted the faster year-over-year revenue change (783.6% vs 2.5%). Over the past eight quarters, Jackson Financial Inc.'s revenue compounded faster (50.1% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Prudential Financial, Inc. is an American financial services company whose subsidiaries provide insurance, retirement planning, investment management, and other products and services to both retail and institutional customers throughout the United States and in over 40 other countries. In 2019, Prudential was the largest insurance provider in the United States with $815.1 billion in total assets. The company is included in the Fortune Global 500 and Fortune 500 rankings.
HOLX vs JXN — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $2.0B |
| Net Profit | $179.1M | $-204.0M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | -18.0% |
| Net Margin | 17.1% | -10.3% |
| Revenue YoY | 2.5% | 783.6% |
| Net Profit YoY | -10.9% | -159.1% |
| EPS (diluted) | $0.79 | $-3.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $2.0B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $-471.0M | ||
| Q1 25 | $1.0B | $3.8B | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $988.0M | $2.1B | ||
| Q2 24 | $1.0B | $1.2B | ||
| Q1 24 | $1.0B | $-322.0M |
| Q4 25 | $179.1M | $-204.0M | ||
| Q3 25 | $187.2M | $76.0M | ||
| Q2 25 | $194.9M | $179.0M | ||
| Q1 25 | $-17.4M | $-24.0M | ||
| Q4 24 | $201.0M | — | ||
| Q3 24 | $178.6M | $-469.0M | ||
| Q2 24 | $194.5M | $275.0M | ||
| Q1 24 | $169.9M | $795.0M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | -18.0% | ||
| Q3 25 | 22.6% | 5.1% | ||
| Q2 25 | 24.9% | — | ||
| Q1 25 | -0.7% | -0.5% | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 23.3% | -27.3% | ||
| Q2 24 | 24.1% | 25.5% | ||
| Q1 24 | 20.7% | — |
| Q4 25 | 17.1% | -10.3% | ||
| Q3 25 | 17.8% | 5.4% | ||
| Q2 25 | 19.0% | -38.0% | ||
| Q1 25 | -1.7% | -0.6% | ||
| Q4 24 | 19.7% | — | ||
| Q3 24 | 18.1% | -22.1% | ||
| Q2 24 | 19.2% | 22.1% | ||
| Q1 24 | 16.7% | -246.9% |
| Q4 25 | $0.79 | $-3.02 | ||
| Q3 25 | $0.84 | $0.92 | ||
| Q2 25 | $0.86 | $2.34 | ||
| Q1 25 | $-0.08 | $-0.48 | ||
| Q4 24 | $0.87 | — | ||
| Q3 24 | $0.75 | $-6.37 | ||
| Q2 24 | $0.82 | $3.43 | ||
| Q1 24 | $0.72 | $9.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $5.7B |
| Total DebtLower is stronger | $2.5B | $2.0B |
| Stockholders' EquityBook value | $5.2B | $10.0B |
| Total Assets | $9.2B | $352.6B |
| Debt / EquityLower = less leverage | 0.48× | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $5.7B | ||
| Q3 25 | $2.2B | $4.6B | ||
| Q2 25 | $1.9B | $3.8B | ||
| Q1 25 | $1.6B | $3.9B | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.3B | $3.1B | ||
| Q2 24 | $2.4B | $1.7B | ||
| Q1 24 | $2.2B | $2.5B |
| Q4 25 | $2.5B | $2.0B | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.5B | $2.0B | ||
| Q1 25 | $2.5B | $2.0B | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | $2.0B | ||
| Q2 24 | $2.5B | $2.0B | ||
| Q1 24 | $2.6B | $2.0B |
| Q4 25 | $5.2B | $10.0B | ||
| Q3 25 | $5.0B | $10.2B | ||
| Q2 25 | $4.8B | $10.4B | ||
| Q1 25 | $4.6B | $10.3B | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $5.1B | $10.7B | ||
| Q2 24 | $5.0B | $10.1B | ||
| Q1 24 | $4.8B | $10.2B |
| Q4 25 | $9.2B | $352.6B | ||
| Q3 25 | $9.0B | $353.6B | ||
| Q2 25 | $8.8B | $343.7B | ||
| Q1 25 | $8.5B | $327.2B | ||
| Q4 24 | $8.7B | — | ||
| Q3 24 | $9.2B | $345.7B | ||
| Q2 24 | $8.9B | $337.8B | ||
| Q1 24 | $8.7B | $340.3B |
| Q4 25 | 0.48× | 0.20× | ||
| Q3 25 | 0.50× | 0.20× | ||
| Q2 25 | 0.52× | 0.20× | ||
| Q1 25 | 0.55× | 0.20× | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | 0.19× | ||
| Q2 24 | 0.51× | 0.20× | ||
| Q1 24 | 0.53× | 0.20× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $1.6B |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $1.6B | ||
| Q3 25 | $355.1M | $1.4B | ||
| Q2 25 | $343.3M | $1.2B | ||
| Q1 25 | $169.4M | $1.6B | ||
| Q4 24 | $189.3M | — | ||
| Q3 24 | $367.0M | $1.4B | ||
| Q2 24 | $405.8M | $1.5B | ||
| Q1 24 | $292.4M | $1.4B |
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — | ||
| Q1 24 | $279.6M | — |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — | ||
| Q1 24 | 27.5% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | 18.03× | ||
| Q2 25 | 1.76× | 6.55× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | 5.37× | ||
| Q1 24 | 1.72× | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
JXN
| Retail Annuities Segment | $1.5B | 74% |
| Closed Life And Annuity Blocks Segment | $298.0M | 15% |
| Institutional Products Segment | $146.0M | 7% |
| Other | $70.0M | 4% |
